Who is sponsoring NCT02694289?

NCT02694289 is sponsored by Maya Guglin.

What condition does NCT02694289 study?

NCT02694289 studies Type 2 Diabetes Mellitus.

What drugs are being tested in NCT02694289?

Interventions: Metformin, Subcutaneous (sliding scale) Insulin.

What is the status of NCT02694289?

NCT02694289 is currently WITHDRAWN.

Last reviewed 2018-11-20 · How we verify

Effects of Metformin in Heart Failure Patients

NCT02694289 NA WITHDRAWN

Hypothesis: In patients, who have diabetes type 2, are treated with metformin, and are admitted for HF, leads to reduced insulin requirements, as measured in units of insulin, with no negative impact on patient safety. This is a single center, prospective trial. Subjects will be randomized to initiate metformin (starting dose 500mg orally once daily up to a maximum dose of 2,500mg daily) OR be placed on insulin products for management of their type 2 diabetes mellitus.

Details

Lead sponsor	Maya Guglin
Phase	NA
Status	WITHDRAWN
Start date	2016-11
Completion	2018-09-10

Conditions

Type 2 Diabetes Mellitus

Interventions

Metformin
Subcutaneous (sliding scale) Insulin

Primary outcomes

Units of Insulin used — from time of hospital admission to hospital discharge, up to one year
doses and amounts on insulin needed